-
Biopharmaceonceons with volume procurement approaching
Time of Update: 2021-03-07
On 17 February, the first day of the new year, CDE issued the Technical Guidelines for the Evaluation of Biosypolor Drug Similarity and Adaptation Extratrophics, which aims to further standardize and
-
Cancer Discov: Venetoclax and Navitoclax, chemotherapy to treat relapse/resuscable acute lymphoblastic leukemia and lymphocytic lymphoma
Time of Update: 2021-02-26
a new study published in Cancer Discovery, "Venetoclax and Navitoclax in Group with Technology in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic" Lymphoma" is a Phase I dose incremental trial (NCT03181126) in which the safety and initial efficacy of venotclax combined small doses of navitoclax and chemotherapy were evaluated in children and adult patients with relapsed/re treatable ALL or LL.
-
JAHA: Plate plate rest therapy in patients with acute coronary artery syndrome who received coronary artery bridge
Time of Update: 2021-02-26
meta-analysis, the researchers compared patients with coronary arterial bridge surgery who had received more effective antiplate plateplate suppression strategies and less effective plateplate suppression strategies, respectively.
-
AP-T: Comparison of direct oral anticoagulants and vitamin K antagonists in the risk of bleeding in the upper digestive tract
Time of Update: 2021-02-26
in order to compare the effects and side effects of new drugs and huafalin, this study analyzed the epidemiology and outcome of upper digestive tract bleeding (UGIB) caused by oral anticoagulant therapy.
outcomes are mortality and bleeding six weeks after UGIB, and the probability of requiring non-endoscopic treatment.
-
The FDA has accepted a new application from BRUKINSA (Zanubrutinib) for the treatment of Waldenström globulinemia
Time of Update: 2021-02-26
The U.S. Food and Drug Administration (FDA) has accepted an application from BRUKINSA (zanubrutinib) for a new drug (sNDA) to treat adult patients with Waldenström globulinemia (WM), the company announced today.
-
BMC Gastroenterology: Angiogen 2 can predict the degree of hemangiogenic and fibrosis in patients with hepatitis C
Time of Update: 2021-02-26
In this study, the researchers aimed to clarify whether blood ANGP-2 could act as a biomarker for liver angiogenesty and fibrosis in CHC patients, and to further reveal the relationship between this pathology in liver fibrosis mouse models treated with carbon tetrachloride (CCl 4).
-
Nat Commun: Placebo controlled trial: Fecal microbiome transplantation to treat HIV
Time of Update: 2021-02-26
researchers report that fecal microbiome transplantation (FMT) is safe, has nothing to do with serious adverse events, and can reduce HIV-related microbiome disorders.
FMT can cause changes in the structure of the gut microbiome, including a significant increase in α diversity, as well as mild and transient transplantation of the supply microbiome during treatment.
-
Blood: Results of clinical trials of BAX 335 gene therapy for type B haemophilia
Time of Update: 2021-02-25
8 adult male subjects (age 20-69 years, FIX activity range: 0.5%-2.0%), received 1 dose with FIX activity, FIX Padua level, liver enzyme level and PBMC-mediated immune response Bax335 intravenously at different dose levels, with a total of 3 dose levels: 2.0×1011, 1.0×1012 or 3.0×1012 carrier genomes/kg.
-
Dig Dis Sci: Serum globulin is associated with endoscopic results and mucous membrane healing in patients with japanese ulcerative colitis
Time of Update: 2021-02-25
This study found a significant positive correlation between serum globulin and endoscopic activity in patients with ulcerative colitis, and significantly negative correlation with mucosal healing, especially in patients with low C-reactive proteins.
-
J Clin Oncol:R-CHOP program plus lynamine can further improve prognostics in newly diagnosed DLBCL patients
Time of Update: 2021-02-25
in this trial, newly diagnosed International Prognostic Index (IPI) ≥2, ECOG Performance Status≤2 of phase II large block-IV DLBCL patients were randomly assigned to the R2CHOP group and R-CHOP group for a total of 6 cycles.
-
Seven years in hospital 22 times, heavy "re-impairment" finally cured! The sick friend was grateful and donated money to convey love
Time of Update: 2021-02-25
7 years of long treatment time, 22 hospitalizations and discharges... After being diagnosed with severe regenerative anemia, Mr. Hu underwent treatment, improvement, recurrence, stem cell transplantat
-
Nature Sub-Journal: In-depth analysis of the global patent landscape for CAR-T therapy
Time of Update: 2021-02-25
However, we can still see that we still have a big gap with the European and American powers - the number of patent institutions, but small size, lack of cooperation and international layout, resulting in a global research and development network in a marginal position.
-
Blood: The efficacy and safety of Flotetuzumab as a remedial immunotherapy for incurable AML patients
Time of Update: 2021-02-25
about 50% of patients with acute myeloid leukemia (AML) do not respond to induction therapy (primary induced failure (PIF)) or relapse within 6 months (early recurrence (ER).
step-by-step dosage, dexamisong pre-treatment, rapid use of toad monoantigen and temporary dose reduction/disruption can successfully prevent the occurrence of severe IRR/CRS.
-
JCO: The treatment of rhonamide combined with R-CHOP can prolong the survival of patients with untreated diffuse large B-cell lymphoma
Time of Update: 2021-02-25
For untreated patients with diffuse large B-cell lymphoma (DLBCL) (including COO and ABC-DLBCL subtypes), the Synadamic Unilidoxi monoantigen-cyclophosphamide-dorobi-star-changchun-neo-alkali-pernisson (R-CHOP) program (R2CHOP) can extend its lifetime.
overall, ECOG-ACRIN E1412 studies have shown potential clinical benefits of adding amine to R-CHOP in the future in newly diagnosed patients, including COO and ABC-DLBCL patients.
-
Clin Cancer Res: VLA4 targets nanoparticles to effectively target the treatment of drug-resistant, incurable myeloma!
Time of Update: 2021-02-24
hypothesed that drug delivery could be targeted using the VLA4 increase of the drug-resistant MMC, which could help improve the safety and effectiveness of treatment.
the targeted delivery and therapeutic activity of NP in human or mouse MMC cells and in-place multiple myeloma mouse models.
-
J Clin Oncol: Eprenetapopt combined with Aza cytosine to treat TP53 mutant MDS and AML
Time of Update: 2021-02-24
Regardless of the treatment, the prognostics of TP53 mutation (TP53m) bone marrow prognostic abnormal syndrome (MDS) and acute myeloid leukemia (AML) were very poor, with only 40% remission rate (full remission rate of 20%) for Azatide (AZA) monotherapy (CR) and short remission duration, with a medium total survival period (OS) of approximately 6 months.
-
Eur J Cancer: Long-term efficacy of Bona Twain anti-anti-treatment in patients with relapsed/refraction Philadelphia chromosome-positive ALL
Time of Update: 2021-02-23
non-recurrence survival rate this analysis included 45 patients who completed the study between January 3, 2014 and January 6, 2017, 16 of whom (35.6%; 95% CI 21.9%-51.2%) obtained CR/CRh in the first two Bonatho monotherapy sessions.
-
AAAAI 2021: PHA121 achieved positive results in the treatment of hereditary angioedema (HAE).
Time of Update: 2021-02-23
25 percent of all subjects treated with PHA121 reported adverse events (AEs), the same rate as 25 percent of placebos.
Peng Lu, chief medical officer of Pharvaris, said: "Oral PHA121 rapidly absorbs within 15 minutes with or without food and exceeds the expected effective treatment threshold.
-
Type A haemophilia, Efanesoctocog alfa granted "fast track eligibility" by FDA
Time of Update: 2021-02-23
Recently, the U.S. Food and Drug Administration (FDA) has granted efanesoctocog alfa "fast-track eligibility" (FTD) for the treatment of haemophilia Type A.
Efanesoctocog alfa adds a regional von Willebrand factor and XTEN®peptide to its innovative Fc fusion technology to extend its half-life.
-
Blood:BH3 map analysis found that ruxolitinib could be used in a joint treatment with ventoclax for pregenuity T lymphocytic leukemia
Time of Update: 2021-02-23
addition, based on the functional method of precision medicine, this study makes it clear that HDAC and JAK/STAT path-inhibitors are promising joint drug options for ventoclax, and it is worth further exploring this joint solution in T-PLL-related clinical trials.
